Lyla Systems

Cover Block

PUBLIC

Attribute	Value
Company Name	Lyla Systems
Tagline	Direct alpha particle measurement for radiopharma QC
Headquarters	Delft, Netherlands
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://lyla.systems/
• LinkedIn: https://www.linkedin.com/in/ernstvdwal/

Executive Summary

PUBLIC

Lyla Systems is developing specialized hardware to solve a critical measurement bottleneck in the production of next-generation radiopharmaceutical cancer therapies, a bet that hinges on technical execution in a nascent but high-stakes market [Yes!Delft, undated]. The company emerged in 2023 from the research ecosystem at TU Delft, with co-founders Ernst van der Wal, Kas Hogeboom, and Bauke van Gameren bringing together physics research, hardware engineering, and software development expertise [Yes!Delft, undated] [LinkedIn, undated]. Its proposed system aims to measure alpha particles directly and in real-time during quality control, a claimed improvement over traditional scintillator-based methods that can miss particle emissions [Yes!Delft, undated].

Capitalization is limited to an undisclosed pre-seed round led by Graduate Entrepreneur, positioning the company in its earliest technical validation phase [Graduate.nl, undated]. The business model targets radiopharmaceutical manufacturers, though no named customers or deployment timelines have been disclosed publicly. For investors, the next 12-18 months will be defined by the transition from prototype to a validated instrument, the securing of initial pilot partnerships with drug developers, and the ability to attract follow-on capital for scaling hardware production.

Data Accuracy: YELLOW -- Core company description and funding event corroborated by multiple Dutch ecosystem sources; specific product claims and team details are sourced from a single incubator profile.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Undisclosed

Company Overview

PUBLIC

Lyla Systems was founded in 2023 in Delft, Netherlands, as a hardware-focused medtech startup emerging from the local research ecosystem [PitchBook]. The company's founding narrative centers on applying novel physics-based measurement to a specific bottleneck in modern cancer therapy development: quality control for radiopharmaceuticals [Yes!Delft].

The founding team consists of three co-founders. Ernst van der Wal, identified as the original researcher, is described as a creative engineer with an educational background from TU Delft and interests in physics and biology [LinkedIn] [Yes!Delft]. His co-founders, Bauke van Gameren and Kas Hogeboom, contribute software and business expertise, respectively [RocketReach] [Yes!Delft]. The company's early development was supported by the YES!Delft incubator, a common launchpad for technical spinouts from the Delft University of Technology [Yes!Delft].

A key early milestone was securing a pre-seed investment from Graduate Entrepreneur, a Dutch venture firm, though the amount and specific date of this round are not publicly disclosed [Graduate.nl]. This capital injection represents the primary public signal of institutional validation for the company's technical premise. No subsequent funding rounds, customer deployments, or product launch dates have been announced in public sources.

Data Accuracy: YELLOW -- Core founding facts confirmed by PitchBook and incubator profile; team details from LinkedIn and secondary aggregators; funding event announced but details are limited.

Product and Technology

MIXED Lyla Systems is developing a hardware and software system designed to measure alpha particles directly during the quality control process for radiopharmaceuticals [Yes!Delft, undated]. The company's public positioning frames this as a technical improvement over established methods, which it claims are prone to inaccuracies and blind spots.

The core product claim is that direct measurement provides superior accuracy for ensuring the potency and safety of next-generation cancer treatments, specifically targeted alpha therapies [Yes!Delft, undated]. While the company's website and press materials do not detail the specific hardware components or software architecture, the narrative emphasizes a real-time measurement capability intended to integrate into pharmaceutical production workflows. No public specifications, performance benchmarks, or images of a working prototype are available for independent verification.

Data Accuracy: YELLOW -- Product claims are sourced from company-affiliated press; no independent technical validation or detailed specifications are publicly available.

Market Research and Opportunity

PUBLIC

Quality control in radiopharmaceutical manufacturing is a niche but critical bottleneck, gaining urgency as targeted alpha therapies progress from clinical trials toward commercial production.

The market Lyla Systems targets is defined by the production and quality assurance of radiopharmaceuticals, particularly those using alpha-emitting isotopes like Actinium-225 or Lead-212. These isotopes are central to a new class of cancer treatments called targeted alpha therapy (TAT), which aims to deliver highly potent radiation directly to cancer cells while minimizing damage to healthy tissue. The global radiopharmaceuticals market is large and growing, with one widely cited report from Grand View Research valuing it at $7.7 billion in 2023 and projecting a compound annual growth rate (CAGR) of 9.5% through 2030 [Grand View Research, 2024]. However, this broad figure encompasses diagnostic agents, established beta-emitter therapies, and the newer alpha-emitters. The specific segment for alpha-particle QC hardware, Lyla's focus, is a small, specialized slice of this broader market, analogous to capital equipment suppliers within biopharma manufacturing.

Demand is driven by the clinical pipeline. Over a dozen TAT candidates are in mid-to-late-stage clinical trials, with the first therapies, such as Bayer's Xofigo (which uses Radium-223, a beta-emitter), having already demonstrated commercial viability for certain cancers. The transition of alpha therapies from research to scaled production creates a direct need for more precise, reliable, and faster QC methods. Current scintillator-based detection systems, while functional, are described by Lyla as having accuracy limitations and "blind spots" [Yes!Delft, undated], a pain point that becomes more acute as production volumes and regulatory scrutiny increase. A secondary driver is the expansion of nuclear medicine infrastructure, supported by government initiatives in the US and Europe to secure domestic isotope supply chains and reduce reliance on foreign production.

Key adjacent markets include the broader medical physics and radiation detection equipment sector, dominated by large players like Mirion Technologies and Thermo Fisher Scientific, and the contract development and manufacturing organization (CDMO) space for radiopharmaceuticals. Companies like NorthStar Medical Radioisotopes and ITM Isotope Technologies Munich are vertically integrating production, which could make them potential partners or customers for a specialized QC system. The regulatory environment is a defining force. Agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require stringent release testing for every batch of a therapeutic radiopharmaceutical. Any new QC technology must ultimately secure regulatory acceptance, a process that can be lengthy but which also creates a high barrier to entry once achieved.

Metric	Value
Global Radiopharmaceuticals Market (2023)	7.7 $B
Projected CAGR (2024-2030)	9.5 %

The available sizing data underscores the significant total addressable market for radiopharmaceuticals, but investors must model Lyla's serviceable market as a fraction of this figure, tied directly to the capital expenditure budgets of alpha-therapy producers and CDMOs. The high growth rate indicates strong tailwinds, though the company's success is contingent on capturing a segment currently served by established, albeit imperfect, alternatives.

Data Accuracy: YELLOW -- Market sizing from a single third-party report; segment-specific sizing for alpha QC hardware is not publicly available.

Competitive Landscape

MIXED, Lyla Systems enters a specialized hardware niche where competition is defined by large, diversified incumbents rather than a crowded field of startups.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Lyla Systems	Direct alpha particle measurement hardware/software for radiopharma QC	Pre-seed; Graduate Entrepreneur [Graduate.nl]	Claims superior accuracy and fewer blind spots vs. scintillator-based methods [Yes!Delft]	[PUBLIC]
Eckert & Ziegler	Diversified provider of isotopes, radiopharma equipment, and services	Public company (ETR:EUZ)	Full-service, vertically integrated supply chain for nuclear medicine	[PUBLIC]
Elysia-Raytest	Manufacturer of radiation measurement and QC equipment	Private, established (founded 1990)	Broad portfolio for radiopharmacy, including dose calibrators and contamination monitors	[PUBLIC]
Alpha Spectra, Inc.	Developer of alpha spectroscopy systems for nuclear measurements	Private, established	Focus on high-resolution alpha spectroscopy for environmental and nuclear safeguards	[PUBLIC]

The competitive map splits into two clear segments. Incumbent equipment manufacturers like Elysia-Raytest and Eckert & Ziegler offer broad portfolios of quality control instruments, including dose calibrators and gamma counters, which are standard in radiopharmacies today. Their advantage is distribution, regulatory familiarity, and being part of a one-stop-shop for production needs. A separate segment consists of specialized spectroscopy firms, such as Alpha Spectra, Inc., which focus on high-precision alpha particle detection, often for research or nuclear safety applications rather than inline pharmaceutical QC.

Lyla's claimed edge rests on a technical wedge: its system is designed for direct, real-time alpha measurement specifically in the radiopharmaceutical workflow, purportedly addressing blind spots inherent in traditional scintillator-based methods used by incumbents [Yes!Delft]. This is a product-level differentiation, not yet a commercial one. The durability of this edge depends entirely on the unproven performance of its proprietary hardware in a regulated production environment. If the accuracy claims are validated by early customers, the edge could be defensible through patents and the high switching costs associated with qualifying new QC equipment under Good Manufacturing Practice (GMP).

The company's most significant exposure is its lack of commercial footprint against entrenched incumbents. Eckert & Ziegler, for example, benefits from deep customer relationships across the entire radiopharma value chain, from isotope supply to finished drug distribution. Lyla does not own any channel and must convince risk-averse producers to adopt a novel instrument from an untested vendor. Furthermore, its focus on alpha-emitting therapies, while forward-looking, currently addresses a smaller subset of the radiopharma market compared to the broader gamma-emitting agents that incumbents' equipment is built to handle.

The most plausible 18-month scenario is one of niche validation or absorption. If Lyla successfully places its systems with a leading radiopharma developer for a targeted alpha therapy program and generates published performance data, it could establish itself as the specialist of choice for next-generation therapies. In that case, a challenger like Alpha Spectra, Inc. might lose share in the specific application of pharmaceutical QC. Conversely, if adoption is slow and incumbents introduce their own improved alpha detection modules, Lyla could find its technical wedge neutralized before achieving commercial scale. The winner in the near term will likely be the player that first secures a referenceable partnership with a top-20 radiopharma manufacturer.

Data Accuracy: YELLOW, Competitor identification is public, but Lyla's differentiation claims are sourced solely from company-associated channels without independent verification.

Opportunity

PUBLIC

If Lyla Systems executes, the prize is a foundational role in the quality control of a new generation of targeted cancer therapies, a market poised for significant expansion as radiopharmaceuticals move from clinical trials to commercial scale.

The headline opportunity is to become the standard for direct alpha measurement in radiopharmaceutical quality control. This outcome is reachable because the company is targeting a specific, growing technical gap. Traditional scintillator-based methods for measuring alpha-emitting isotopes, the active ingredients in therapies like targeted alpha therapy (TAT), are described as having accuracy limitations and "blind spots" [Yes!Delft, undated]. Lyla's proposed hardware/software system aims for real-time, direct measurement, a capability that would address a concrete pain point in ensuring the potency and safety of these high-value, perishable drugs. As the radiopharma sector scales, standardized, reliable QC becomes non-negotiable for regulators and manufacturers alike, creating a clear path for a specialized tool to become category-defining infrastructure.

Growth would likely follow one of several concrete scenarios, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
The Delft Standard	Lyla's system is adopted as the preferred QC tool within the dense Dutch and European radiopharma ecosystem, starting with academic spinouts and CROs.	A partnership with a major European nuclear research facility or a contract with a local radiopharma producer (e.g., at the Bio Science Park Leiden).	The founders emerged from the TU Delft research environment via the YES!Delft incubator [Yes!Delft, undated], providing natural early access to a network of potential first customers in adjacent life sciences hubs.
The Platform Pivot	The core alpha measurement hardware becomes a module within a broader, software-driven QC and data management platform for radiopharma manufacturing.	The release of a software suite that integrates dose calibration, batch record-keeping, and regulatory reporting, leveraging data from the hardware sensor.	The founding team explicitly combines hardware and software expertise [Yes!Delft, undated], and the value in medtech increasingly shifts to data aggregation and workflow integration, not just instrumentation.

What compounding looks like for Lyla is a classic example of a precision-engineering moat. Each deployment in a production or research setting generates proprietary data on alpha particle behavior under various conditions. This dataset could refine the system's detection algorithms, creating a feedback loop where the product becomes more accurate and reliable with use. Furthermore, integration into a manufacturer's QC workflow creates switching costs; once a method is validated for a drug submission, changing instrumentation requires re-validation, a significant regulatory and time burden. Early design wins could therefore lead to entrenched, long-term customer relationships.

The size of the win can be framed by looking at comparable providers of specialized radiopharma equipment. Publicly traded Eckert & Ziegler, a named competitor, operates a Radiopharma segment and has a market capitalization in the hundreds of millions of euros. A successful niche player capturing a specific, high-value segment of the QC equipment market could command a valuation reflecting its strategic importance. If the "Platform Pivot" scenario plays out, the company could transition from a hardware vendor to a higher-margin software and services business, potentially achieving valuation multiples more akin to specialized life sciences software tools. This outcome represents a scenario, not a forecast, but it illustrates the potential scale for a company that successfully defines a new standard in a critical, high-growth therapeutic area.

Data Accuracy: YELLOW -- Opportunity analysis is based on cited product claims and market context; specific growth catalysts and comparables are extrapolated from the available landscape.

Sources

PUBLIC

1. [Yes!Delft, undated] Lyla: Quality control for the next generation of cancer treatment | https://yesdelft.com/stories/lyla-quality-control-for-the-next-generation-of-cancer-treatment/

2. [Graduate.nl, undated] New pre-seed investment: LYLA | https://www.graduate.nl/insights/new-pre-seed-investment-lyla

3. [PitchBook] Lyla Systems 2025 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/749220-94

4. [LinkedIn, undated] Ernst van der Wal - Lyla | LinkedIn | https://www.linkedin.com/in/ernstvdwal/

5. [RocketReach, undated] Bauke van Gameren Email & Phone Number | LYLA Co-founder and Software lead Contact Information | https://rocketreach.co/bauke-van-gameren-email_9152128

6. [Grand View Research, 2024] Global Radiopharmaceuticals Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/radiopharmaceuticals-market